Key Takeaways
Extended Takeaways
- Among 2,267 analyzable responses, zap onset latency tracked antidepressant half-life: long half-life agents had longer onset than the other groups, and medium half-life drugs also had longer latency than paroxetine and (des)venlafaxine (P < .0001, χ2 = 144.6).
- Lateral eye or head movement appears to be a particularly useful diagnostic clue: 1,012 respondents named eye or head movements as a trigger, and 203 more reported unspecified “movement,” suggesting a vestibulo-ocular component to many cases.
- Clinicians should not assume brain zaps are brief nuisances only; 17% rated the impact as “overwhelming,” about 40% each reported “significant or “some” negative effects, and only 54 respondents reported no noticeable effect.
- Most respondents were still symptomatic when surveyed, with 2,103 of 2,267 reporting ongoing brain zaps; among those rating change over time, 876 said symptoms were “as bad as ever” or “worse,” while only 120 said they had gotten much better.
- When patients describe associated neurologic features, vertigo may be especially relevant: there were 647 descriptions of neurologic signs, and almost half were vertigo, supporting a vestibular framing rather than dismissing the symptom as nonspecific anxiety.
- Professional response was often absent or unhelpful in this sample: 1,313 respondents did not report symptoms to a professional, and among 413 prescriber recommendations, heterogeneous nonantidepressant approaches were described as barely or not at all helpful.
